DEFA14A ·Filed Jun 25, 2026

TECH

BIO-TECHNE Corp
BULLISH
Impact 8/10
Horizonmonths Processed3mo ago SEC0001999371-26-013514
Proxy solicitation materials
Actionable Insight ▲ Bullish

The $73.00 per share cash offer provides a clear floor for TECH stock, which should trade near that level minus deal risk and time value. Monitor regulatory and shareholder approval processes; any delays or competing bids could create volatility. Traders should consider the deal premium relative to pre-announcement price and the probability of closing.

DirectionBullish
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
TECH ▲ +2.07% at T+60d
LONG call ✓ call won +2.07% · α vs SPY -4.04% · entry $71.00 → $72.47
Entry anchored
Jun 25, 03:59 PM ET
via exchange tick
T+1d
-0.14%
call -0.14% · α -1.79%
$70.90
settled 3mo ago
T+5d
-0.24%
call -0.24% · α -2.41%
$70.83
settled 3mo ago
T+20d
+1.08%
call +1.08% · α -0.18%
$71.77
settled 2mo ago
T+60d
+2.07%
call +2.07% · α -4.04%
$72.47
settled 11d ago

Price Chart

Loading chart...

Executive Summary

Bio-Techne has entered into a definitive agreement to be acquired by Merck KGaA for $73.00 per share in cash. The deal is expected to close by late 2026 or early 2027, subject to shareholder and regulatory approvals. This definitive additional proxy soliciting material communicates the terms and seeks support for the merger.

Key Facts

  • Acquisition price: $73.00 per share in cash
  • Expected close: late 2026 or early 2027
  • Subject to shareholder approval and regulatory approvals
  • Employee stock options and RSUs will be cashed out at $73.00 per share

Financial Impact

$73.00 per share cash consideration for all outstanding shares of Bio-Techne

acquisition premiumcash consideration

Risk Factors

  • Regulatory approvals may not be obtained or could be delayed
  • Shareholders may reject the deal
  • A competing offer could emerge or the deal could be renegotiated

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
73% bullish (22 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001999371-26-013514
Document: 0001999371-26-013514-index-headers.html0001999371-26-013514
Document: 0001999371-26-013514-index.html0001999371-26-013514
Document: 0001999371-26-013514.txt0001999371-26-013514
4 reports for TECH
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for TECH — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
8-K
BULLISH ★ 7/10
$72.23 $72.08▼ −0.21%▲ +1.69%$72.42 (+0.26%)
Aug 12, 2026
7w ago
Press Release
NEUTRAL ★ 4/10
$72.23 $72.08▼ −0.21%▲ +1.69%$72.42 (+0.26%)
Aug 10, 2026
7w ago
PREM14A
BULLISH ★ 7/10
$72.15 $72.25▲ +0.14%▲ +1.20%$72.42 (+0.37%)
Jun 25, 2026
14w ago
DEFA14A
BULLISH ★ 8/10
$71.00 $71.77▲ +1.08%▼ −0.18%$72.42 (+1.99%)
Showing 4 of 4

US Market Status

Market Open — Closes in 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access